BRIEF-Plus Therapeutics Completes Enrollment In Second ReSPECT-LM Phase 1 Trial Cohort

Reuters
Feb 01, 2023

Feb 1 (Reuters) - Plus Therapeutics Inc :

* PLUS THERAPEUTICS COMPLETES ENROLLMENT IN SECOND RESPECT-LM PHASE 1 TRIAL COHORT OF RHENIUM (¹⁸⁶RE) OBISBEMEDA FOR THE TREATMENT OF LEPTOMENINGEAL METASTASES

* PLUS THERAPEUTICS INC - INITIAL DATA FROM PHASE 1/PART A IS ANTICIPATED IN SECOND HALF OF 2023

Source text for Eikon: Further company coverage:

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10